DalsnaFinance Account

Aura Biosciences Inc $AURA

Health Care

Russell 2000 Massachusetts

Create a scorecard

$6.55

+0.26 (+4.05%)

As of Oct 20, 2026, 12:44 PM EDT

Price history

Loading chart…

Aura Biosciences Inc (AURA) is trading up at $6.55 (+4.05%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

IPO: October 29, 2021 · $14.00 offering · NASDAQ · View IPO details →

Aura Biosciences Inc net income history (FY2020–FY2025)

Net income

Aura Biosciences Inc annual financial statements
	FY2020Dec 2020	FY2021Dec 2021	FY2022Dec 2022	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Operating income	−$22.2M	−$35.3M	−$60.3M	−$85.0M	−$96.1M	−$112.8M
Net income	−$22.2M	−$35.3M	−$58.8M	−$76.4M	−$86.9M	−$106.2M
EPS (diluted)	−$82.06	−$8.95	−$1.96	−$1.93	−$1.75	−$1.76
Balance sheet
Cash and equivalents	$17.4M	$149.1M	$121.6M	$41.1M	$31.7M	$59.5M
Total assets	$22.1M	$160.0M	$223.9M	$255.1M	$182.5M	$169.4M
Total liabilities	$2.74M	$7.71M	$28.4M	$29.2M	$30.5M	$32.5M
Shareholders' equity	−$108.7M	$152.3M	$195.6M	$225.8M	$152.0M	$136.9M
Cash flow
Operating cash flow	−$24.3M	−$32.4M	−$54.6M	−$63.8M	−$79.8M	−$84.7M
Capital expenditure	$771.0K	$2.13M	$1.09M	$709.0K	$1.25M	$447.0K
Free cash flow	−$25.1M	−$34.5M	−$55.7M	−$64.6M	−$81.1M	−$85.2M

Net income

Aura Biosciences Inc quarterly financial statements
	Q3 FY24Sep 2024	Q4 FY24^†Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25^†Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Income statement
Operating income	−$23.2M	−$27.8M	−$29.0M	−$28.6M	−$27.9M	−$27.2M	−$34.9M	−$48.1M
Net income	−$21.0M	−$25.8M	−$27.5M	−$27.0M	−$26.1M	−$25.6M	−$33.7M	−$45.6M
EPS (diluted)	−$0.42	−$0.52	−$0.55	−$0.47	−$0.40	−$0.34	−$0.50	−$0.48
Balance sheet
Cash and equivalents	$25.4M	$31.7M	$38.2M	$107.4M	$47.6M	$59.5M	$84.8M	$67.8M
Total assets	$205.3M	$182.5M	$155.4M	$204.4M	$190.0M	$169.4M	$137.7M	$348.1M
Total liabilities	$30.7M	$30.5M	$27.4M	$29.8M	$33.4M	$32.5M	$30.4M	$32.9M
Shareholders' equity	$174.7M	$152.0M	$128.0M	$174.6M	$156.7M	$136.9M	$107.2M	$315.3M
Cash flow
Operating cash flow	−$15.3M	−$24.0M	−$23.4M	−$20.8M	−$20.1M	−$20.5M	−$29.9M	−$32.5M
Capital expenditure	$341.0K	$299.0K	$187.0K	$39.0K	$45.0K	$176.0K	$102.0K	$21.0K
Free cash flow	−$15.6M	−$24.3M	−$23.5M	−$20.8M	−$20.2M	−$20.6M	−$30.0M	−$32.5M

From Aura Biosciences Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →